Researchers have developed a self-amplifying RNA (saRNA) therapy that could offer a simpler way to support heart recovery after myocardial infarction. Delivered via a lipid nanoparticle and a single intramuscular injection, the approach enabled sustained production of a heart-protective hormone in preclinical models, according to a study published in Science.
The therapy delivers instructions for natriuretic peptide type A, which produces atrial natriuretic peptide—a hormone involved in cardiovascular regulation. Unlike conventional mRNA, the saRNA platform allows the body to continue producing the protein for an extended period at lower doses.
In mouse and swine models, a single injection produced the hormone for more than 4 weeks and led to improved cardiac function, reduced infarct size, and less fibrosis — even in models with conditions such as diabetes and atherosclerosis.
“This is about helping the heart tap into its own healing mechanisms,” said co-author Dr. Ke Huang. “[T]he idea that a single shot might offer support for weeks is very exciting.”
The treatment was designed to avoid more invasive delivery methods used in earlier approaches, instead relying on a standard intramuscular injection.
“Our goal is to protect the heart right when it’s most vulnerable,” said Dr. Huang said, “If we can ease that early stress and support repair, we may be able to change the trajectory of recovery for patients.”
The researchers will continue to study safety, timing, and dosing before moving toward human trials.
https://www.science.org/doi/10.1126/science.adu9394
Newsletters
Receive the latest pharmaceutical news, personalities, education, and career development – weekly to your inbox.
